EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

2023/03/16 by Bernhard Hellmich, Beatriz Sánchez‐Álamo, Beatriz Sanchez-Alamo +36 · 38 citations
Medicine · #Vasculitis and related conditions #Systemic Sclerosis and Related Diseases #Otitis Media and Relapsing Polychondritis

paper · pdf · doi:10.1136/ard-2022-223764

Citations

• Long-term patient survival in ANCA-associated vasculitis

Cited by

• Mosunetuzumab, a CD20xCD3 bispecific T-cell engager, in granulomatosis with polyangiitis
• Therapeutic management of inflammatory heart diseases
• Top ten tips in managing ANCA vasculitis
• Preventing infections in immunocompromised patients with kidney diseases: vaccines and antimicrobial prophylaxis
• Characteristics and risk factors for infection in patients with ANCA-associated vasculitis: A systematic review and meta-analysis
• Overlapping forms of granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis: Insights from a European multicenter study
• Making use of avacopan in clinical practice
• Cardiovascular involvement in ANCA-associated vasculitis
• Survey on Plasmapheresis Practices in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis: Insights From Two Clinical Case Studies
• It's Friday, 3 p.m., and the phone rings ... a practical approach to common nephrology consultations—Part 1
• Patients’ experiences of managing their rare rheumatic disease
• Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee
• Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice
• Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations. [europepmc]
• Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV. [europepmc]
• Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1-treatment of granulomatosis with polyangiitis and microscopic polyangiitis. [europepmc]
• Eosinophilic Granulomatosis with Polyangiitis: Latest Findings and Updated Treatment Recommendations. [europepmc]
• The involvement of NETs in ANCA-associated vasculitis. [europepmc]
• Renal involvement in eosinophilic granulomatosis with polyangiitis. [europepmc]
• GEMA 5.3. Spanish Guideline on the Management of Asthma. [europepmc]
• ANCA-associated vasculitis-treatment standard. [europepmc]
• Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial. [europepmc]
• Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases. [europepmc]
• Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective. [europepmc]
• Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics. [europepmc]
• Oxidative Stress: A Culprit in the Progression of Diabetic Kidney Disease. [europepmc]
• Prevalence, incidence and healthcare burden of eosinophilic granulomatosis with polyangiitis in the UK. [europepmc]
• Defects in B-lymphopoiesis and B-cell maturation underlie prolonged B-cell depletion in ANCA-associated vasculitis. [europepmc]
• Vignette-based comparative analysis of ChatGPT and specialist treatment decisions for rheumatic patients: results of the Rheum2Guide study. [europepmc]
• Therapy of IgA nephropathy: time for a paradigm change. [europepmc]
• Granulomatosis with polyangiitis: clinical characteristics and updates in diagnosis. [europepmc]
• Avacopan in Anti-Neutrophil Cytoplasmic Autoantibodies-Associated Vasculitis in a Real-World Setting. [europepmc]
• Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study. [europepmc]
• Vasculitis in Children. [europepmc]
• Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy. [europepmc]
• Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan. [europepmc]
• Long-Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis. [europepmc]
• The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis. [europepmc]